Company
MTx is a HK-based start-up biotech company that develops first-in-class, first-in-industry drug discovery technology and small molecule drugs. MTx pioneers in the field of liquid-liquid phase separated biomolecular condensate-targeted drugs (condensate drugs). MTx’ founders have recently published their findings describing the first small molecule capable of inhibiting a functional condensate resulting in a therapeutic effect in an animal model of Respiratory Syncytial Virus (Risso-Ballester, Nature, 2021). The company’s vision is to generate patent-protected pre-clinical and clinical stage assets for out-licensing and partnering with pharma. Medusa Tx aims to become the first company to develop a condensate drug to the clinical proof of concept stage and ultimately to market in order to provide critically needed treatment options for life-threatening infectious diseases and cancer.
Description
Pioneering small molecule drugs targeting pathological biomolecular condensates in infectious disease and oncology
